Charles Schwab’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Charles Schwab’s Portfolio PNT Stock Details PNT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-689,179	Closed	-$4.6M	–	3577
2023 Q3	$4.6M	Buy	689,179 +446,910	+184%	+$3.71M	﹤0.01%	2299
2023 Q2	$2.19M	Buy	242,269 +10,196	+4%	+$89.9K	﹤0.01%	2516
2023 Q1	$1.69M	Buy	232,073 +11,569	+5%	+$85.8K	﹤0.01%	2569
2022 Q4	$1.61M	Buy	220,504 +28,274	+15%	+$210K	﹤0.01%	2632
2022 Q3	$1.49M	Buy	192,230 +441	+0.2%	+$3.74K	﹤0.01%	2669
2022 Q2	$1.31M	Buy	191,789 +162,711	+560%	+$1.25M	﹤0.01%	2697
2022 Q1	$232K	Hold	29,078	–	–	﹤0.01%	3281
2021 Q4	$163K	Hold	29,078	–	–	﹤0.01%	3387
2021 Q3	$224K	Buy	+29,078	New	+$265K	﹤0.01%	3309

Other funds holding PNT

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Charles Schwab's PNT Position: Q4 2023 in Review

Charles Schwab sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 689,179 shares — an estimated $4.6M sold.

Charles Schwab first reported a position in PNT in Q3 2021 and held it in 9 quarters. The position peaked at $4.6M in Q3 2023. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

Charles Schwab reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
Charles Schwab sold 689,179 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $4.6M.
Charles Schwab first reported a position in POINT Biopharma Global Inc. Common Stock in Q3 2021 and held it in 9 quarters.
Charles Schwab's POINT Biopharma Global Inc. Common Stock position peaked at $4.6M in Q3 2023.
1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Charles Schwab's 13F filing for Q4 2023, filed 6 Feb 2024.